76 related articles for article (PubMed ID: 7698532)
1. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
Ammann M; Kinney MAO; Gudmundsdottir H; Santol J; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Anderson AL; Halfdanarson TR; Nagorney DM; Starlinger PP
Ann Surg Oncol; 2024 Jun; 31(6):3976-3977. PubMed ID: 38619707
[No Abstract] [Full Text] [Related]
2. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
McCully BH; Kozuma K; Pommier S; Pommier RF
Ann Surg Oncol; 2024 May; 31(5):2996-3002. PubMed ID: 38227166
[TBL] [Abstract][Full Text] [Related]
3. Proton-pump inhibitor-induced bone loss is preventable by concomitant use of a long-acting somatostatin analogue.
Koohpeyma F; Taghiyan S; Shams M
Iran J Basic Med Sci; 2024; 27(2):165-169. PubMed ID: 38234669
[TBL] [Abstract][Full Text] [Related]
4. Multimodal Treatment of Vasoactive Intestinal Polypeptide-producing Pancreatic Neuroendocrine Tumors with Liver Metastases.
Iwasaki M; Tsuchida K; Jinnai H; Komatsubara T; Arisaka T; Tsunemi M; Nakano M; Iijima M; Hiraishi H
Intern Med; 2017; 56(5):517-522. PubMed ID: 28250297
[TBL] [Abstract][Full Text] [Related]
5. Surgical resection of vasoactive intestinal peptideoma with hepatic metastasis aids symptom palliation: A case report.
Zhang X; Zhou L; Liu Y; Li W; Gao H; Wang Y; Yao B; Jiang D; Hu P
Exp Ther Med; 2016 Mar; 11(3):783-787. PubMed ID: 26997993
[TBL] [Abstract][Full Text] [Related]
6. Insulinoma.
Burns AR; Dackiw AP
Curr Treat Options Oncol; 2003 Aug; 4(4):309-17. PubMed ID: 12943611
[TBL] [Abstract][Full Text] [Related]
7. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors.
Schell SR; Camp ER; Caridi JG; Hawkins IF
J Gastrointest Surg; 2002; 6(5):664-70. PubMed ID: 12399054
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options.
Nguyen HN; Backes B; Lammert F; Wildberger J; Winograd R; Busch N; Rieband H; Matern S
Dig Dis Sci; 1999 Jun; 44(6):1148-55. PubMed ID: 10389687
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of carcinoids of the stomach].
Becker HD; Gabriel A
Langenbecks Arch Chir; 1996; 381(1):18-22. PubMed ID: 8717170
[TBL] [Abstract][Full Text] [Related]
10. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
11. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.
Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1989 Mar; 34(3 Suppl):28S-39S. PubMed ID: 2537716
[TBL] [Abstract][Full Text] [Related]
12. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
Arnold R; Frank M; Kajdan U
Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
Arnold R; Neuhaus C; Trautmann ME
Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
[No Abstract] [Full Text] [Related]
14. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors.
Trautmann ME; Neuhaus C; Lenze H; Benning R; Benning M; Dennler HJ; Bruns C; Joseph K; Arnold R
Horm Metab Res Suppl; 1993; 27():24-7. PubMed ID: 8392487
[No Abstract] [Full Text] [Related]
15. [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].
Blanchin M; James-Deidier A; Chaumet-Riffaud PD; Chayvialle JA
Presse Med; 1992 Apr; 21(15):697-702. PubMed ID: 1376476
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
